The number-one challenge facing the biopharmaceutical industry today is public distrust, dwarfing concerns about regulatory obstacles or the sheer difficulty of the science required to develop drugs, a survey of STAT Plus subscribers shows.

Much of the public’s poor opinion of biopharma stems from runaway drug price hikes, and survey respondents had a lot to say about strategies being pursued in Washington to corral these costs. They give high marks to the tax law and brush off any concern about import tariffs.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • This is an annoying story. When reporting on survey results it’s pretty common to actually show the results, in the form of graphs and tables for each question. In this story, we are at the mercy of qualitative interpretation.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy